Mechanistic and clinical insights at the scleroderma-cancer interface

Research output: Contribution to journalReview articlepeer-review

Abstract

Emerging data suggest tantalizing links between cancer and systemic inflammatory rheumatic syndromes. In scleroderma, patients may have an increased risk of cancer, secondary to chronic inflammation and damage from the disease, malignant transformation promoted by immunosuppressive therapies, a shared susceptibility to both cancer and autoimmunity, or a common inciting exposure. However, it is increasingly recognized that a subset of patients develop cancer around the time that scleroderma clinically manifests, raising the question of cancer-induced autoimmunity. In this review, we discuss data suggesting a mechanistic link between cancer and the development of scleroderma, and the clinical implications of these findings.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalJournal of Scleroderma and Related Disorders
Volume2
Issue number3
DOIs
StatePublished - 2017

Keywords

  • Autoantibodies
  • Malignancy
  • Systemic sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Mechanistic and clinical insights at the scleroderma-cancer interface'. Together they form a unique fingerprint.

Cite this